<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02004288</url>
  </required_header>
  <id_info>
    <org_study_id>CSUB0083</org_study_id>
    <nct_id>NCT02004288</nct_id>
  </id_info>
  <brief_title>The Role of Lactobacillus Reuteri in Children and Adolescents With Anorexia Nervosa</brief_title>
  <official_title>The Role of Lactobacillus Reuteri in Nutritional Recovery and Treatment of Constipation in Children and Adolescents With Anorexia Nervosa - Randomised, Double Blind, Placebo Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioGaia AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioGaia AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate whether Lactobacillus reuteri could have a beneficial&#xD;
      role in treatment of children and adolescents with Anorexia nervosa who develop motility&#xD;
      disorder due to the malnutrition regarding the normalization of the motility, as well as the&#xD;
      possible role of probiotics on nutritional recovery, especially on bone health.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pediatric patients with AN and constipation referred to gastroenterologist for nutritional&#xD;
      rehabilitation at the Department of Pediatric Gastroenterology, Hepatology and Nutrition,&#xD;
      Clinical Hospital Center Sestre Milosrdnice, Zagreb, approximately 30 children, will be asked&#xD;
      to participate.&#xD;
&#xD;
      The evaluation of patients will be conducted through APA DSM-V diagnostic criteria for&#xD;
      anorexia nervosa and Rome III criteria for constipation.&#xD;
&#xD;
      During the hospitalization all of the patients will receive conventional nutritional&#xD;
      rehabilitation that is composed of serving normal food under supervision of nurses that&#xD;
      calculate daily caloric intake through 5-6 meals and according to that additional enteral&#xD;
      nutrition that consist of polymeric enteral formula. Daily caloric intake is calculated as&#xD;
      kcal/kg/day and is slowly rising through 2 weeks starting from 80% to the goal of 130% of&#xD;
      daily energy requirements according to FAO 2004 recommendation.&#xD;
&#xD;
      Anthropometry measures will be taken at the time of hospitalization and at every visit.&#xD;
&#xD;
      Normalization of weight is when the Z-score for BMI is less than -1.5 according to CDC&#xD;
      BMI-growth charts, or normalisation of menstrual cycle is achieved.&#xD;
&#xD;
      In order to achieve adherence to therapeutic protocol parents will be contacted by phone at&#xD;
      least once in 7-10 days. Participants will be instructed to keep diary on a daily basis&#xD;
      (adherence to therapy, stool diary). All patients will return packages with all used, and&#xD;
      unused product.&#xD;
&#xD;
      BASELINE -VISIT 1 Randomization at first day of hospitalization. In all patients&#xD;
      anthropometry will be performed at the time of hospitalization, as well as dual-energy X-ray&#xD;
      absorptiometry (DEXA) and serum D3 levels at first 2 days of hospitalization as a part of&#xD;
      routine diagnostic protocol in heavily underweight patients with AN.&#xD;
&#xD;
      VISIT 2 4 weeks after randomization, at discharge from hospital Anthropometry&#xD;
&#xD;
      VISIT 3 8 weeks after randomization, 4 weeks after discharge from hospital Anthropometry&#xD;
&#xD;
      END OF STUDY -VISIT 4 3 months after baseline Anthropometry&#xD;
&#xD;
      VISIT 5 3 months after the end of study (6 months after baseline) At this point control serum&#xD;
      D3 levels and DEXA will be performed at all patients Anthropometry&#xD;
&#xD;
      All the symptoms and daily caloric intake will be monitored using diaries attached to&#xD;
      protocol.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants That Drop Out From Rome III Criteria for Constipation</measure>
    <time_frame>3 month</time_frame>
    <description>Drop out from Rome III criteria for constipation: Yes / No. According to Rome III, a diagnosis of functional constipation is made when at least two of the following criteria are met for the last 3 months with symptom onset at least 6 months prior to diagnosis: a) straining on &gt;25% of defecations; b) lumpy or hard stools on &gt;25% of defecations; c) sensation of incomplete evacuation on &gt;25% of defecations; d) sensation of anorectal obstruction/blockage on &gt;25% of defecations; e) manual maneuvers on &gt;25% of defecations; and f) less than 3 defecations per week.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Normalization of Body Weight</measure>
    <time_frame>6 month</time_frame>
    <description>normalization of body weight- 90% of premorbid weight, or ≥10. centile for BMI (according to the WHO growth charts)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Anorexia Nervosa</condition>
  <condition>Constipation</condition>
  <arm_group>
    <arm_group_label>Lactobacillus reuteri Protectis DSM17938</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One chewable tablet twice per day with L reuteri Protectis DSM 17938, 1x108 CFU/tablet (colony forming unit)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One chewable tablet twice per day with placebo per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lactobacillus reuteri Protectis DSM17938</intervention_name>
    <description>One chewable tablet with L. reuteri or placebo taken twice a day for 3 months. After the 3 month therapy both groups will be monitored for the next 3 months.</description>
    <arm_group_label>Lactobacillus reuteri Protectis DSM17938</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pediatric patients with Anorexia nervosa and constipation, aged 8-18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  AN and constipation present for less than 3 month prior to hospitalization&#xD;
&#xD;
          -  any disease that affects GI or other systems other than AN or functional constipation&#xD;
&#xD;
          -  chronic disorder other than AN&#xD;
&#xD;
          -  receiving probiotic and/or prebiotic products 14 days prior to enrolment&#xD;
&#xD;
          -  receiving antibiotics 14 days prior to enrolment&#xD;
&#xD;
          -  constipation prior AN&#xD;
&#xD;
          -  receiving laxative as a therapy for constipation or abuse of laxative to lose weight&#xD;
             prior to enrolment&#xD;
&#xD;
          -  extraintestinal symptoms: fever, rash&#xD;
&#xD;
          -  abnormalities in laboratory findings&#xD;
&#xD;
          -  abnormalities in clinical findings: organomegaly, perianal disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Orjena Zaja Franulovic, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Eating disorders Sestre milosrdnice University hospital Zagreb, Croatia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pediatric Department Clinical Hospital Centre Sestre milosrdnice Gastroenterology, Hepatology and Nutrition Ward</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Croatia</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>December 2, 2013</study_first_submitted>
  <study_first_submitted_qc>December 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2013</study_first_posted>
  <results_first_submitted>May 28, 2021</results_first_submitted>
  <results_first_submitted_qc>May 28, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 22, 2021</results_first_posted>
  <last_update_submitted>June 22, 2021</last_update_submitted>
  <last_update_submitted_qc>June 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Probiotics</keyword>
  <keyword>Anorexia nervosa</keyword>
  <keyword>Constipation</keyword>
  <keyword>Body weight</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constipation</mesh_term>
    <mesh_term>Anorexia</mesh_term>
    <mesh_term>Anorexia Nervosa</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Lactobacillus Reuteri Protectis DSM17938</title>
          <description>One chewable tablet twice per day with L reuteri Protectis DSM 17938, 1x108 CFU/tablet (colony forming unit)&#xD;
Lactobacillus reuteri Protectis DSM17938: One chewable tablet with L. reuteri or placebo taken twice a day for 3 months. After the 3 month therapy both groups will be monitored for the next 3 months.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>One chewable tablet twice per day with placebo per day&#xD;
Lactobacillus reuteri Protectis DSM17938: One chewable tablet with L. reuteri or placebo taken twice a day for 3 months. After the 3 month therapy both groups will be monitored for the next 3 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lactobacillus Reuteri Protectis DSM17938</title>
          <description>One chewable tablet twice per day with L reuteri Protectis DSM 17938, 1x108 CFU/tablet (colony forming unit)&#xD;
Lactobacillus reuteri Protectis DSM17938: One chewable tablet with L. reuteri or placebo taken twice a day for 3 months. After the 3 month therapy both groups will be monitored for the next 3 months.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>One chewable tablet twice per day with placebo per day&#xD;
Lactobacillus reuteri Protectis DSM17938: One chewable tablet with L. reuteri or placebo taken twice a day for 3 months. After the 3 month therapy both groups will be monitored for the next 3 months.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="31"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                    <count group_id="B2" value="16"/>
                    <count group_id="B3" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                    <count group_id="B2" value="16"/>
                    <count group_id="B3" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.06" spread="2.31"/>
                    <measurement group_id="B2" value="15.13" spread="1.70"/>
                    <measurement group_id="B3" value="15.06" spread="1.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                    <count group_id="B2" value="16"/>
                    <count group_id="B3" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Croatia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                    <count group_id="B2" value="16"/>
                    <count group_id="B3" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants That Drop Out From Rome III Criteria for Constipation</title>
        <description>Drop out from Rome III criteria for constipation: Yes / No. According to Rome III, a diagnosis of functional constipation is made when at least two of the following criteria are met for the last 3 months with symptom onset at least 6 months prior to diagnosis: a) straining on &gt;25% of defecations; b) lumpy or hard stools on &gt;25% of defecations; c) sensation of incomplete evacuation on &gt;25% of defecations; d) sensation of anorectal obstruction/blockage on &gt;25% of defecations; e) manual maneuvers on &gt;25% of defecations; and f) less than 3 defecations per week.</description>
        <time_frame>3 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lactobacillus Reuteri Protectis DSM17938</title>
            <description>One chewable tablet twice per day with L reuteri Protectis DSM 17938, 1x108 CFU/tablet (colony forming unit)&#xD;
Lactobacillus reuteri Protectis DSM17938: One chewable tablet with L. reuteri or placebo taken twice a day for 3 months. After the 3 month therapy both groups will be monitored for the next 3 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>One chewable tablet twice per day with placebo per day&#xD;
Lactobacillus reuteri Protectis DSM17938: One chewable tablet with L. reuteri or placebo taken twice a day for 3 months. After the 3 month therapy both groups will be monitored for the next 3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants That Drop Out From Rome III Criteria for Constipation</title>
          <description>Drop out from Rome III criteria for constipation: Yes / No. According to Rome III, a diagnosis of functional constipation is made when at least two of the following criteria are met for the last 3 months with symptom onset at least 6 months prior to diagnosis: a) straining on &gt;25% of defecations; b) lumpy or hard stools on &gt;25% of defecations; c) sensation of incomplete evacuation on &gt;25% of defecations; d) sensation of anorectal obstruction/blockage on &gt;25% of defecations; e) manual maneuvers on &gt;25% of defecations; and f) less than 3 defecations per week.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Normalization of Body Weight</title>
        <description>normalization of body weight- 90% of premorbid weight, or ≥10. centile for BMI (according to the WHO growth charts)</description>
        <time_frame>6 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lactobacillus Reuteri Protectis DSM17938</title>
            <description>One chewable tablet twice per day with L reuteri Protectis DSM 17938, 1x108 CFU/tablet (colony forming unit)&#xD;
Lactobacillus reuteri Protectis DSM17938: One chewable tablet with L. reuteri or placebo taken twice a day for 3 months. After the 3 month therapy both groups will be monitored for the next 3 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>One chewable tablet twice per day with placebo per day&#xD;
Lactobacillus reuteri Protectis DSM17938: One chewable tablet with L. reuteri or placebo taken twice a day for 3 months. After the 3 month therapy both groups will be monitored for the next 3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Normalization of Body Weight</title>
          <description>normalization of body weight- 90% of premorbid weight, or ≥10. centile for BMI (according to the WHO growth charts)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During the study, 6 months / participant,</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Lactobacillus Reuteri Protectis DSM17938</title>
          <description>One chewable tablet twice per day with L reuteri Protectis DSM 17938, 1x108 CFU/tablet (colony forming unit)&#xD;
Lactobacillus reuteri Protectis DSM17938: One chewable tablet with L. reuteri or placebo taken twice a day for 3 months. After the 3 month therapy both groups will be monitored for the next 3 months.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>One chewable tablet twice per day with placebo per day&#xD;
Lactobacillus reuteri Protectis DSM17938: One chewable tablet with L. reuteri or placebo taken twice a day for 3 months. After the 3 month therapy both groups will be monitored for the next 3 months.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The limitation of this study is the small number of patients. This is due to strict inclusion and exclusion criteria, as well as the fact that some parents and patients refused to participate in the survey, which is not unusual given the negativism that characterizes this disease.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Orjena Žaja, MD MSc PhD primarius Ass Prof Pediatrics, Pediatric gastroenterologist</name_or_title>
      <organization>Sestre milosrdnice University Hospital Center Vinogradska 29, Zagreb, Croatia</organization>
      <phone>P:+38513787342 M:+3859937872</phone>
      <email>Orjena Žaja &lt;orjenazf@yahoo.com&gt;</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

